207_Combined course Presentations

DAHANCA19: Acute morbidity

Confluent mucositis

Grade 3-4 in-field reaction

80

80

Maximum difference at day14 after end of RT: p<0.0001

zalutumumab

60

60

Control

40

40

zalutumumab

20

20

0

0

control

Maximum difference in week 5: p=0.001

Percentage in-field grade 3+4 (%)

Percentage confluent mucositis (%)

W1 W2 W3 W4 W5 End RT 14 day 2 months W1 W2 W3 W4 W5 End 2Wk 2Mo

W1 W2 W3 W4 W5 End RT 14 day 2 months W1 W2 W3 W4 W5 End 2Wk 2Mo

Need for tube-feeding at end of treatment: No difference (50% vs. 50%)

Eriksen, ICHNO 2015